A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Recurrent Glioblastoma
Latest Information Update: 09 May 2025
At a glance
- Drugs Izalontamab brengitecan (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 28 Oct 2024 Status changed from not yet recruiting to recruiting.
- 27 Sep 2024 New trial record